GlassScriptPhysician profile
Amy M Perlmutter
NPI 1174786941
$7,519.30
in general payments reported to CMS, 2019-2025
30 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $291 · 2021: $1,409 · 2022: $1,056 · 2023: $1,272 · 2024: $1,120 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.73 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,545.40 | 2019-2025 | Nemluvio |
| Abbvie INC. | $952.36 | 2021-2025 | |
| Genzyme Corporation | $561.71 | 2022-2025 | |
| Amgen INC. | $525.27 | 2020-2025 | Otezla, Otezla |
| Allergan, INC. | $461.26 | 2019-2022 | |
| Incyte Corporation | $434.65 | 2024-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $423.41 | 2021-2024 | Tremfya |
| Leo Pharma INC. | $314.45 | 2020-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $313.95 | 2022-2025 | |
| Journey Medical Corporation | $312.28 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $239.56 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $220.71 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $200.57 | 2023-2025 | Zoryve |
| Merz North America, INC. | $151.91 | 2021-2022 | |
| Dermavant Sciences, INC. | $151.90 | 2023-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $137.90 | 2019 | |
| Epi Health, LLC | $131.09 | 2022 | |
| Lilly USA, LLC | $84.22 | 2020-2024 | Olumiant, Ebglyss, Taltz |
| Almirall LLC | $67.63 | 2019-2024 | Klisyri |
| Revance Therapeutics, INC. | $40.91 | 2024 | Daxxify |
| Vyne Pharmaceuticals INC. | $38.22 | 2020-2021 | |
| Botanix Sb INC | $30.51 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $29.55 | 2024-2025 | Xtrac |
| Organon LLC | $28.26 | 2025 | Vtama |
| Pfizer INC. | $27.22 | 2020 | |
| Mayne Pharma Commercial LLC | $22.78 | 2019 | |
| Biofrontera INC. | $20.15 | 2022 | |
| Genentech USA, INC. | $19.98 | 2020 | |
| Ucb, INC. | $17.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.